Cooperative Agreement U01CA296639
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $691K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $585,458 to Baylor College of Medicine to further validate and refine a mass spectrometry-based proteomic assay for early detection of pancreatic ductal adenocarcinoma (PDAC). The project aims to: 1) determine the performance characteristics and robustness of the assay for clinical utilization; 2) refine the assay's accuracy and thresholds for PDAC detection...
- This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
- This Cooperative Agreement was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $525,013 award will fund research to validate blood-based biomarkers for assessing lung cancer risk among individuals with no smoking history, using samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The research aims to...
- This federal Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $739,640 to the Fred Hutchinson Cancer Center to develop methods for advancing the early detection of pancreatic ductal adenocarcinoma (PDAC) by leveraging electronic medical records (EMR) data. The key objectives of the project are to: Better define the at-risk population for PDAC beyond just new-onset diabetes, including those with new-onset prediabetes and...
- This $941,798 Cooperative Agreement was awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Beckman Research Institute of the City of Hope, a nonprofit medical research organization in California. The funding supports research to investigate the molecular mechanisms of codon-biased translation, a process that cancer cells hijack to promote their survival and therapeutic resistance. Specifically, the project will explore the role of the ALKBH1 enzyme in...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) in the amount of $653,819 aims to redefine screening for early detection of pancreatic cancer. The grant will be used by The Johns Hopkins University to: Develop a highly specific blood-based early detection screening test called "PancSeek" for populations at higher risk of pancreatic cancer. Develop risk models that integrate clinical, genomic, molecular, and...
- This Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,281,520.00 in funding to The Leland Stanford Junior University to conduct research on the fundamental biological mechanisms of cancer metastasis, organ tropism, and immune evasion. The project aims to integrate genetic barcoding with single-cell profiling to uncover the key molecular drivers underlying metastatic fitness and diverse cancer cell states in pancreatic ductal...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $210,600 to the Regents of the University of Michigan to analytically validate and evaluate an H3K27M circulating tumor DNA (ctDNA) assay for monitoring diffuse midline glioma (DMG) patients. The project aims to establish the analytical performance characteristics of this high-sensitivity ctDNA assay as a CLIA-compliant laboratory developed test (LDT) and then...
- This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $398,398 to Cold Spring Harbor Laboratory (CSHL) to conduct research on identifying natural product-derived inhibitors of the KLK6 enzyme as a strategy to prevent the progression of preneoplastic ductal pancreatic cancer. The funding supports a multi-year project to leverage CSHL's expertise in cancer biology, genomics, and computational...